Skip to main content

Cui Xiangmin's Form 4 filing

Aardvark Therapeutics, Inc. (AARD) · filed Feb 19, 2025

Accession no.
0000950170-25-023409
Filed
Feb 19, 2025, 5:44 PM ET
Trade date
Feb 14, 2025
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $20.0M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cui XiangminCIK 000148781510% Owner
Decheng Capital Global Life Sciences Fund IV, L.P.CIK 000183415010% Owner
Decheng Capital Management IV (Cayman), LLCCIK 000184338410% Owner
Decheng Capital Global Healthcare Fund (Master), LPCIK 000194902610% Owner
Decheng Capital Global Healthcare GP, LLCCIK 000194902710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 14, 2025Common StockCConversionAcquired+2,333,887––2,333,887Indirect
Feb 14, 2025Common StockCConversionAcquired+333,412––333,412Indirect
Feb 14, 2025Common StockPPurchaseAcquired+625,000$16.00+$10,000,0002,958,887Indirect
Feb 14, 2025Common StockPPurchaseAcquired+625,000$16.00+$10,000,000958,412Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 14, 2025Common StockCConversionDisposed−2,333,887$0.00$00Indirect
Feb 14, 2025Common StockCConversionDisposed−333,412$0.00$00Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)